Polidocanol

Description

Polidocanol is used for the treatment of uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the legs, a condition where the veins become large, twisted and swollen when the vein valves do not work properly. This medicine is not recommended for use in patients less than 18 years of age.

Side effects

Major & minor side effects for Polidocanol

  • Bleeding
  • Severe pain, burning, or irritation in legs
  • Discoloration of the skin
  • Severe headache
  • Itching
  • Swelling, warmth, or redness in one or both legs
  • Numbness
  • Dizziness
  • Swelling and redness at the injection site
  • Trouble breathing

Uses of Polidocanol

What is it prescribed for?

  • Varicose veins
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. If the medicine is used, close monitoring of the infant for any undesired side effects is recommended.

Allergy

This medicine is not recommended for use if you have a known allergy to Polidocanol or any other inactive ingredients present along with it.

Acute thromboembolic disease

This medicine is not recommended for use in patients with acute thromboembolic diseases, a condition of formation of blood clot in the blood vessels due to the increased risk of worsening of the patient's condition.

Thrombophilia

This medicine is not recommended for use in patients with thrombophilia (blood coagulation abnormality) due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. If the medicine is used, close monitoring of the infant for any undesired side effects is recommended.
General warnings

Venous thrombosis

This medicine may cause venous thrombosis (clot formation within a vein) or other thrombotic events and should be used with extreme caution in patients with a history of deep vein thrombosis (clot formation in a deep vein), recent (within 3 months) major surgery, or prolonged hospitalization due to the increased risk for developing a blood clot. Close monitoring of clinical condition, appropriate dose adjustments or replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Use in children

This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.

Anaphylactic reactions

This medicine may cause severe allergic reactions, including anaphylactic shock in some patients. Appropriate corrective treatments, dose adjustments or replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Extravasation

This medicine has to be administered very carefully to avoid extravasation, as this can cause severe tissue necrosis.

Missed Dose

Since this medicine is administered in the hospital or clinic setting by a qualified healthcare professional, the likelihood of a missed dose is very low.

Overdose

Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Propylene Glycol

Peginterferon Alfa-2B

Disease interactions

Disease

Information not available.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine should be administered by a qualified healthcare professional in the clinical or hospital setting. Inform the doctor if you have a known history of allergy to this medicine. Report to the doctor all your current medicines as well as your medical conditions before receiving this medicine. Report any undesirable side effects to the doctor promptly.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

Does not cause sleepiness

How it works
This medicine increases the formation of blood clots and scar tissue inside the veins and thus immediately helps to shrink the enlarged veins.
Legal Status

Approved

Approved

Approved

Unknown

Classification

Category

Sclerosing agents

Schedule

Schedule H

Polidocanol - DrugBank [Internet]. Drugbank.ca. 2019 [cited 2 January 2019]. Available from:

https://www.drugbank.ca/drugs/DB06811

Polidocanol [Internet]. Pubchem.ncbi.nlm.nih.gov. 2019 [cited 2 January 2019]. Available from:

https://pubchem.ncbi.nlm.nih.gov/compound/Polidocanol

[Internet]. Accessdata.fda.gov. 2019 [cited 2 January 2019]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021201lbl.pdf

[Internet]. Pdf.hres.ca. 2019 [cited 2 January 2019]. Available from:

https://pdf.hres.ca/dpd_pm/00041869.PDF

[Internet]. Btgplc.com. 2019 [cited 2 January 2019]. Available from:

https://btgplc.com/BTG/media/Varithena/materials/Varithena_Full_Prescribing_Information.pdf

DailyMed - Asclera - polidocanol injection, solution [Internet]. Dailymed.nlm.nih.gov. 2019 [cited 2 January 2019]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90550274-6605-44de-8c25-c5591080270f

How will this medicine affect me?

Consult top doctors online and get an answer now
Consult now
Consult now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 4 Feb 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.